In recent years, the successive approvals of two new drugs have once again brought a chemokine receptor into the spotlight. In 2023, the FDA approved Motixafortide (brand name Aphexda) in combination with long-acting G-CSF for hematopoietic stem cell mobilization in patients with multiple myeloma. Then in 2024, the FDA approved Mavorixafor (Xolremdi) for the treatment […]
CCR1 (C-C motif chemokine receptor 1) is a G protein-coupled receptor (GPCR) involved in inflammatory responses and immune cell migration. In recent years, with the deepening research on immune-related diseases and the tumor microenvironment, CCR1 has gradually emerged as an important therapeutic target for autoimmune diseases, tumors, and organ fibrosis. 1. Overview of CCR1 Chemokine monomers […]
Acute myeloid leukemia (AML) is a complex and highly heterogeneous hematologic malignancy closely associated with various cytogenetic and chromosomal abnormalities. Among them, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are one of the most common genetic alterations. Studies have shown that approximately 25% of AML patients carry FLT3 internal tandem duplication mutations (FLT3-ITD), while about […]
Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, the linker, and the payload. Previously, we summarized the research progress in bispecific ADCs. Here, we further consolidate the pipeline updates of dual-payload ADCs.
In the drug development efforts targeting complex diseases such as neuropsychiatric disorders, metabolic dysregulation, and cancer, the neuropeptide Y (NPY) receptor family is garnering increasing attention from researchers and pharmaceutical companies alike. As a typical subfamily of G protein-coupled receptors (GPCRs), NPY receptors not only regulate a variety of physiological processes but also play critical […]
At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such as bispecific ADCs and dual-toxin ADCs, forming a unique landscape at the AACR meeting. Here, we summarize the key players and target pipelines in the bispecific ADC (BsADC) space, based on AACR data.
The 116th AACR Annual Meeting will be held from April 25 to 30, 2025, at the McCormick Place Convention Center in Chicago, USA. Among the 6,470 abstracts released for the 2025 AACR, there are 340 related to antibody-drug conjugates (ADCs), covering various types such as single-target ADCs, dual-target ADCs, and dual-payload ADCs. These involve numerous […]
In recent years, the rapid development of AI-driven drug discovery (AI-based drug discovery) and Cryo-EM (cryo-electron microscopy) has gradually unveiled the mysteries of many previously considered “undruggable” protein targets. Among them, membrane proteins, which are crucial targets for drug development, are now seeing unprecedented breakthroughs under the dual influence of AI and Cryo-EM technologies. However, membrane protein […]
In recent years, Antibody-Drug Conjugates (ADCs) have gained widespread attention as a key strategy in targeted cancer therapies. The effectiveness of ADCs relies on the specific targeting of the antibody, efficient internalization, and the release of the payload toxin. Therefore, evaluating both the internalization efficiency and cytotoxicity introduced by antibody-payload complex is crucial in ADC […]
The 2025 American Association for Cancer Research (AACR) Annual Meeting is set to take place in Chicago, USA, from April 25 to 30. The recently released conference abstracts highlight the strong presence of Chinese biopharmaceutical companies in the field of antibody-drug conjugates (ADCs). At this year’s conference, Chinese pharmaceutical companies dominate the ADC field, presenting […]